Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand

Dermavant Sciences Inc. is launching its first commercial drug, which management believes has enormous revenue-generating potential in a large therapeutic category – plaque psoriasis. The US Food and Drug Administration approved Dermavant's Vtama (tapinarof) cream 1% on 23 May, with a broad label for adults with plaque psoriasis, paving the way for the topical cream to be used across the spectrum of disease severity from mild to severe.

The Roivant-owned company has big expectations for Vtama because it is a non-steroidal topical treatment that could replace topical steroid-based drugs as a first-line treatment for plaque psoriasis and also may be used in combination with systemic oral and injectable therapies for more severe patients. Vtama is the first new chemical entity within the topical plaque psoriasis treatment space to launch in 25 years